New study data show that prescription patterns differed depending on the type of institution they were prescribed in and the specialty of prescribing physicians.
Prescription patterns of topical medications for atopic dermatitis changed between 2002 and 2015, according to the results of a new study. Patterns differed depending on the type of institution they were prescribed in and the specialty of prescribing physicians.
Results of the investigative review were published in Annals of Dermatology.
Topical corticosteroids (TCSs) are considered the main anti-inflammatory treatment for acute atopic dermatitis flares. However, thanks to the introduction of new topical calcineurin inhibitors (TCIs), prescription patterns of topical agents have shifted, authors explained.
“It is important to understand these patterns of changes to increase patient compliance and to provide structured long-term treatment. However, to date, most studies have focused on the individual efficacy of topical agents and there has been no comprehensive study on the overall prescribing patterns of topical medications for [atopic dermatitis] in Korea,” they wrote.
To better characterize this change, the researchers analyzed medications prescribed to Korean patients with atopic dermatitis based on data from the National Health Insurance Sharing System. They also compared the potency of any prescribed TCSs for patients with atopic dermatitis vs psoriasis.
A total of 94,165 patients were included in the study, with the annual number of patients receiving treatment ranging from 5743 to 9340 between 2002 and 2015.
TCSs were the most prescribed topical medications among patients, the authors said. These were followed by topical antibiotics and TCIs. Over the period studied, “estimates indicated a slight decrease in prescription rates of TCSs from 95.4% to 92.0%, but there was no significant difference.”
Additional findings included the following:
The prevalence of atopic dermatitis in Korea is around 9.5% in children under age 10 and just over 1% in those older than age 10. The overall prevalence is 1.9% among the entire Korean population.
Although TCSs have several advantages over other treatments, such as their availability in varying potencies and formulations, over the long term the medications can lead to local adverse effects (AEs) like rosacea, acne, and skin atrophy.
“Severe systemic AEs, including the suppression of the hypothalamic-pituitary adrenal axis, hyperglycemia, diabetes, and glaucoma, can occur,” the authors added.
Because TCIs have targeted anti-inflammatory effects without local or systemic AEs, they can serve as an appropriate alternative treatment for patients with atopic dermatitis.
The study researchers hypothesize a higher proportion of TCI and topical antibiotic prescriptions were made at tertiary hospitals because there is a higher proportion of patients using TCIs as maintenance therapy in tertiary hospitals. “These institutions treat more chronic patients with severe conditions that are difficult to manage in primary and secondary hospitals,” they noted.
However, as new topical agents like phosophodiesterase-4 and Janus kinase inhibitors emerge, prescription patterns will likely continue to change and become more diverse in the future.
“Therefore, to provide effective and safe treatment options for [atopic dermatitis] patients, more constructed topical treatment prescription algorithms are needed,” researchers concluded.
Reference
Lee J, Kim T, Cheon S, et al. Prescription patters of topical medications in patients with atopic dermatitis: an investigative review using big data from the national health insurance corporation. Ann Dermatol. Published online March 9, 2023. doi:10.5021/ad.22.114
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Reveals Decline in Inpatient Dermatology Services and Urgent Need for Strategic Support
May 17th 2024A recent study found significant regional disparities and a decline in inpatient dermatology encounters and providers across the US from 2013 to 2019, highlighting the need for increased support and improved access to specialized dermatologic care.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More